Post hoc analysis of moderately and severely affected patients ( baseline National Institutes of Health Stroke Scale , @ and @ ) showed greater National Institutes of Health Stroke Scale improvements in the @ mg/d cutamesine group when compared with placebo ( P = @ and P = @ , respectively ) .